
    
      A 6 week randomized, double blind placebo controlled trial in healthy young adults aged 18 to
      50. Participants will be administered an oral dose of B. subtilis or placebo (1 capsule/day)
      for a period of 4 weeks. Viable counts will be measured from stool samples to assess transit
      survival, daily questionnaires (DQ) will be administered to assess general wellness, and
      gastrointestinal (GI) symptoms will be evaluated three times with the Gastrointestinal
      Symptom Response Scale (GSRS) questionnaire.
    
  